RxDoctor Payments Data

Mark Vogel, MD

Cardiovascular Disease · Saint Louis, MONPI 1497984983

Payments from drug & device makers

$1,034in general payments, 2019–2025

Across 26 payments — averaging $39.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$367
  • Heartflow, Inc.$148
  • Actelion Pharmaceuticals US, Inc.$134
  • Abbott$81
  • Amgen$75
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$57
  • plus $172 from 6 others

What the payments were for

  • Food & beverage$1,034100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,034 in reported general payments places this provider in the 35th percentile of 391 cardiovascular disease providers in Missouri.

See all cardiovascular disease providers in Missouri

Medicare billing

Part B allowed, 2024
$171,927
Medicare patients
1,933
Services billed
2,918

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban811$903,458
XareltoRivaroxaban187$209,152
Repatha SureclickEvolocumab119$97,058
EntrestoSacubitril/Valsartan53$39,988
BrilintaTicagrelor30$28,280
Praluent PenAlirocumab35$25,088
JardianceEmpagliflozin20$23,154
Atorvastatin Calcium712$6,652
Midodrine Hcl27$5,682
Potassium Chloride124$3,952
Metoprolol Succinate309$3,320
Ranolazine ErRanolazine27$3,265
Amlodipine Besylate357$2,597
Carvedilol312$2,148
Hydralazine Hcl160$2,128

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$47$903,458811 claims
Johnson & JohnsonXarelto$30$209,152187 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 391 cardiovascular disease providers in Missouri.

Other cardiovascular disease in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →